U.K. decision blocks a pair of Alzheimer’s drugs from access through its national health service
A U.K. health agency said the Alzheimer’s drugs Kisunla and Leqembi are not cost-effective, meaning they won’t be offered through the NHS.
Related Articles
U.S. drops charges against doctor accused of throwing away Covid shots, selling fake vaccine cards
The doctor allegedly destroyed $28,000 of Covid shots and provided fake vaccine cards.
Federal judge tosses Blue Cross Blue Shield of Louisiana lawsuit, another loss for Medicare Advantage insurers
The Medicare Advantage industry has aggressively sued the federal government to overturn reduced quality ratings and keep billions of taxpayer-funded bonuses.
Ending the federal LGBTQ+ suicide prevention line is a public health failure
Ending the federal LGBTQ+ suicide prevention line is a public health failure, write two leaders in prevention and crisis response.
US drops charges against doctor accused of destroying Covid vaccines
US Attorney General Pam Bondi said the doctor ‘gave patients a choice when the federal government refused to do so’.
Fundraising in academia and the Epstein problem
Philanthropy can provide enormous benefits, and should be encouraged, but it can also create terrible reputational damage when a donor turns out to be toxic,…
UnitedHealth’s Campaign to Quiet Critics
The company has invoked the murder of an executive last year to complain about coverage in news outlets, on streaming services and on social media.
UnitedHealth’s Campaign to Quiet Critics
The company has invoked the murder of an executive last year to complain about coverage in news outlets, on streaming services and on social media.
There’s now a chance for bipartisan health care policies, but partisan tensions are running high
A lot stands in the way of bipartisan health care policymaking, threatening PBM reform and extenders.
Use of antibiotic to reduce STIs appears to be fueling some antibiotic resistance, research shows
The use of the antibiotic doxycycline to reduce STIs appears to be fueling some antibiotic resistance, according to new research.
FDA rejects Capricor’s cell therapy for Duchenne muscular dystrophy
The FDA rejected a Duchenne muscular dystrophy cell therapy from Capricor Therapeutics, as a larger study of the treatment continues.